An, Meirui http://orcid.org/0000-0002-4006-8670
Raguram, Aditya
Du, Samuel W. http://orcid.org/0000-0002-9655-3659
Banskota, Samagya
Davis, Jessie R.
Newby, Gregory A.
Chen, Paul Z. http://orcid.org/0000-0001-5261-1610
Palczewski, Krzysztof http://orcid.org/0000-0002-0788-545X
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UG3AI150551, U01AI142756)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Howard Hughes Medical Institute (Liu Investigatorship)
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY009339)
Article History
Received: 18 June 2023
Accepted: 30 November 2023
First Online: 8 January 2024
Competing interests
: The authors declare competing financial interests: M.A., A.R., S.B. and D.R.L. have filed patent applications on this work through the Broad Institute. S.B. is currently a consultant for Nvelop Therapeutics. J.R.D. is currently an employee of Prime Medicine. K.P. is a consultant for Polgenix, Alnylam and AbbVie, Inc. D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver genome editing or epigenome engineering agents. The remaining authors declare no competing interests. Correspondence: drliu@fas.harvard.edu.